Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in...

Area of Science:

• Gastroenterology
• Immunology
• Microbiology

Background:

• Current ulcerative colitis (UC) treatments primarily manage symptoms through immune suppression, which carries risks and often fails to halt disease progression.
• A significant unmet need exists for novel, safe, and effective UC treatments that address the disease upstream of symptom management.
• Existing therapies often involve long-term immune inhibition, increasing risks of infection and malignancy.

Purpose of the Study:

• To evaluate QBECO, a microbial-based treatment designed to activate mucosal immune function, as a novel therapeutic approach for UC.
• To assess the efficacy and safety of QBECO in preclinical models of colitis and in a clinical trial for UC patients.

Main Methods:

• Utilized chemically-induced DSS colitis and Muc2-deficient mouse models to evaluate QBECO's ameliorative effects on gastrointestinal disease.
• Conducted a 16-week open-label trial in moderate-to-severe UC patients to test QBECO's safety, tolerability, and clinical/histopathological improvements.

Main Results:

• QBECO treatment significantly reduced inflammation and promoted mucosal and histological healing in both experimental colitis models and UC patients.
• Preclinical studies indicated QBECO ameliorated mucosal pathology by decreasing inflammatory cell infiltration, particularly neutrophils and T cells.
• UC patients treated with QBECO experienced a notable reduction in rectal bleeding as the most immediate clinical improvement.

Conclusions:

• This study demonstrates that strategically activating immune function, rather than suppressing it, can effectively reduce UC disease pathology.
• QBECO treatment shows promise as a novel therapeutic strategy for ulcerative colitis, offering a new mechanism of action.
• The findings suggest that immune activation may be a viable alternative to immune suppression for managing UC.